When a patient with renal cell carcinoma (RCC) progresses on or following the combination of a tyrosine kinase inhibitor (TKI ...

We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...

As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

Data from the longitudinal ColoCare study (NCT02328677) of patients with colorectal cancer add to a growing body of evidence ...

Transportation is a key accessibility issue for patients with HR-positive metastatic breast cancer receiving CDK4/6 ...

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

The frontline combination of zanidatamab-hrii (Ziihera) and chemotherapy with or without tislelizumab (Tevimbra) was ...

A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...

Zolbetuximab plus mFOLFOX6 and nivolumab led to meaningful gains in patients with unresectable gastric/gastroesophageal junction adenocarcinoma. The frontline combination of zolbetuximab (Vyloy), ...

Destiny-Breast09 PROs demonstrated higher quality of life and fewer gastrointestinal symptoms in patients with HER2-positive advanced breast cancer. Patient-reported outcomes (PROs) from the phase 3 ...